Xponance Inc. Cuts Stock Position in Hologic, Inc. $HOLX

Xponance Inc. cut its position in Hologic, Inc. (NASDAQ:HOLX) by 26.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 36,504 shares of the medical equipment provider’s stock after selling 13,224 shares during the quarter. Xponance Inc.’s holdings in Hologic were worth $2,464,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of HOLX. Winnow Wealth LLC purchased a new stake in Hologic during the third quarter valued at approximately $26,000. Root Financial Partners LLC acquired a new position in shares of Hologic during the third quarter worth $27,000. SJS Investment Consulting Inc. lifted its holdings in shares of Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 362 shares during the last quarter. Loomis Sayles & Co. L P acquired a new stake in shares of Hologic in the 2nd quarter worth $33,000. Finally, Smartleaf Asset Management LLC grew its stake in Hologic by 168.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 494 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 310 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Price Performance

NASDAQ:HOLX opened at $75.45 on Tuesday. The company has a 50 day moving average price of $74.96 and a 200-day moving average price of $72.22. The firm has a market cap of $16.84 billion, a price-to-earnings ratio of 31.44, a price-to-earnings-growth ratio of 2.24 and a beta of 0.73. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $75.49. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. Hologic’s revenue was up 2.5% on a year-over-year basis. During the same quarter last year, the business earned $0.87 earnings per share. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on HOLX shares. BNP Paribas Exane cut Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target for the company. in a research note on Friday, November 21st. Morgan Stanley boosted their target price on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Evercore cut shares of Hologic from an “outperform” rating to an “in-line” rating and decreased their price target for the stock from $79.00 to $78.00 in a report on Monday, January 5th. Argus downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a research report on Tuesday, November 4th. Two investment analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $78.42.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.